A CU Medicine provider.
Qualifications and experience
- Languages spoken
Memorial Sloan-Kettering Cancer Center Program (1995)
University of Toronto (1987)
Queen's University, Kingston, Ontario, Canada (1986)
University of Toronto (1994)
University of Toronto (1993)
- Clinical interest for patients
I have suspended my clinical practice in order to focus on research and administration of the cancer center
- Research interest for patients
Working on a disease that has seen few advances in the last 30 years, Theodorescu has emerged as a leading translational bladder cancer researcher. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as discovery of new drugs for several cancer types. Examples include discovery of genes that regulate tumor growth and metastasis (RhoGDI2, CD24, AGL, GON4L) in bladder and other cancers and novel biomarkers (DNA/NGS, RNA and proteomic) and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG) clinical trials. He led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in several human cancer types which is now in commercial development. Recent efforts in our lab have focused on understanding the biology of Telomerase reverse transcriptase (TERT) and using that knowledge to develop novel inhibitors to this critical protein in cancer. Finally, active efforts are currently aimed at identifying immune system agonists or antagonists that modulate tumor behavior in vivo as well as the identification of novel combination therapies that enhance the effectiveness of checkpoint and other immunotherapy.
- UCHealth strongly encourages you to consult with your health insurer to determine accurate information about your coverage and benefits for a particular health care service provided at a UCHealth facility. Read more here.